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L E T T E R S T O T H E E D I T O R
Results of the prematurely terminated
TEMPLE randomized controlled trial in
patients with myelodysplastic syndrome:
liberal versus restrictive red blood cell
transfusion threshold
To the Editor:
Red blood cell (RBC) transfusion is the cornerstone in the
treatment of patients with myelodysplastic syndromes (MDS) to
improve health related quality of life (HRQoL). Only very limited
data is available on the optimal transfusion trigger in this set-
ting.1 The Temple (Transfusion Effects in Myelodysplastic
Patients: Limiting Exposure) Study was a multicenter, random-
ized, non-inferiority clinical trial that compared a restrictive
(Hb transfusion trigger <4.5 mmoL/L, <7.3 g/dL) with a standard
(liberal) transfusion policy (Hb transfusion trigger <6.0 mmoL/L,
<9.7 g/dL) in patients with MDS. Primary endpoint was physical
fatigue, measured with the Multidimensional Fatigue Inventory
(MFI).2 The study was conducted at one university and two gen-
eral hospitals in the Netherlands and ethical approval was given
by the University of Rotterdam’s Institutional Review Board
(MEC-198.887/2001/41) and all participating hospitals.
Adult patients (≥18 years of age) diagnosed with MDS
according to the French-American-British (FAB) classification3
and dependent on RBC transfusion (e.g., who had ≥1 RBC trans-
fusion recently) were eligible. Exclusion criteria were candidates
for stem cell transplantation, use of growth factors (e.g., G-CSF,
GM-CSF or erythropoietin), myelo-ablative chemotherapy,
patients with the diagnosis Refractory Anemiawith Excess Blasts
in Transformation, pregnancy, patients with hemolytic anemia
or congenital hemolytic disorders, severe infectious disease,
and severe cardiac, pulmonal, or neurological co-morbidity at
time of inclusion. Patients were not aware of the Hb levels dur-
ing the study where physicians and nurses were aware of the
group assignments. All participants had a run-in period of
3 months with a transfusion-threshold of 6 mmoL/L (9.7 g/dL)
followed by 12 months follow up after randomization. During
this run-in periodMDSdiagnosis was confirmed by an indepen-
dent reference committee. After 3 months patients were allo-
cated in a 1:1 ratio to the liberal or the restrictive arm. For both
groups standard 2 units of RBC were transfused. RBC transfu-
sion was allowed if severe symptoms of anemia developed or at
their physician’s discretion. HRQoL scores,2 physical complica-
tions and blood values were recorded. Other outcomes were
number of RBC transfused, transfusion reactions, length of hos-
pital stay, and mortality. With a sample size of 200 patients
(100 per study arm), differences of 0.4SD inMFI physical fatigue
scores were detectable (α = 0.05, β = 0.20).2 As a non-inferiority
design trial, the study was not adequately powered to detect
clinically relevant differences.
From July 2002 till August 2004 21MDSpatients consented
to take part in the study (Fig. 1). During the 3 months run-in
period, one patient died and one patient withdrew informed
consent. After 3 months, 19 patients were randomized: 10 for
the restrictive arm and 9 for the liberal arm (Table 1). No signifi-
cant differences were found for patient characteristics between
the 2 study groups. After randomizationHb levels were lower in
the restrictive arm leading to 17% less transfusions of RBC units
compared to the liberal group. Reasons to transfuse were simi-
lar for the restrictive group and the liberal group. No transfusion
reactionswere reported in both groups.
The Temple study was terminated prematurely due to the
slow recruitment rate with only 21 patients in three hospitals in
2 years. Patients who were still participating when the study
ended, received transfusion therapy according to the guidelines
of the local hospital. After randomization 6 out of 10 patients
(60%) from the restrictive and 5 out of 9 patients (55.5%) from the
liberal arm completed or still participated when the study termi-
nated. Reasons of study withdrawal were withdrawal of informed
consent (two in the restrictive and one in the liberal arm), death
(one in the restrictive and two in the liberal arm) and usage of
growth factors (one patient in each arm). No significant differ-
ences were found for dizziness, headache, confusion, syncope,
cerebrovascular ischemia, cardiac failure, cardiac ischemia/
infarction, palpitations, tachycardia, and development of RBC
allo-antibodies. Results of the HRQoL are shown in Table 1. The
main reason for termination of the study was the slow inclusion
rate rather than the dropout percentage. Fear of the low Hb trig-
ger in these elderly patients was the main reason not to ask
patients for the study. In our higher aged population (mean
75 years) with a relatively poor prognosis, the patients’ compli-
ance to the protocol was high with a participation rate after
1.5 year of approximately 60%. The restrictive RBC transfusion
Fig. 1. CONSORT diagram of the Temple study.
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policy led to a reduction of 17% in RBC transfusions without car-
diac complications. Although many clinical trials involve RBC
transfusion triggers in acute anemia,4,5 evidence in chronic ane-
mia is lacking. Data of the Temple study can be helpful and used
as pilot study for further clinical research for which (interna-
tional) collaboration is necessary.
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TABLE 1. Patient and RBC transfusion characteristics
Restrictive transfusion thresholdA (N = 10) Liberal transfusion thresholdB (N = 9)
Age (years)





Refractory anemia (RA) 2 1
Refractory anemia with ring sideroblasts (RARS) 4 1
Refractory Anemia with excess blasts (RAEB) 0 2
Refractory anemia with multilineage dysplasia (RCMD) 4 5
Chronic myelomonocytic leukemia (CMML) 0 0
Hemoglobin value at randomization (Mean (range))
T = −3 months (mmol/l / g/dL) 5.6 (5.0–6.5) / 9.0 (8.1–10.5) 5.5 (4.8–6.4) / 8.9 (7.7–10.3)
T = 0 (mmol/l / g/dL) 6.0 (5.4–7.1) / 9.7 (8.7–11.4) 6.0 (4.7–7.4) / 9.7 (7.6–11.9)
T = 6 weeks (mmol/l / g/dL) 5.3 (4.1–6.2) / 8.5 (6.6–10.0) 5.7 (5.1–6.2) / 9.2 (8.2–10.0)
T = 3 months (mmol/l / g/dL) 5.5 (4.6–6.7) / 8.9 (7.4–10.8) 5.7 (4.9–6.1) / 9.2 (7.9–9.8)
T = 6 months (mmol/l / g/dL) 5.2 (4.6–6.3) / 8.4 (7.4–10.2) 6.0 (5.1–6.8) / 9.7 (8.2–11.0)
T = 9 months (mmol/l / g/dL) 4.6 (4.6–4.6) / 7.4 (7.4–7.4) 5.1 (5.1–5.1) / 8.2 (8.2–8.2)
T = 12 months (mmol/l / g/dL) 4.5 (4.4–4.5) / 7.3 (7.1–7.3) 5.2 (5.2–5.2) / 8.4 (8.4–8.4)
Total follow-up time (months) 8,6 (1–15) 6,9 (2–14)
RBC characteristics (N)
Total RBC transfusions after randomization 21 26
Total units RBC transfused 43 52
Reasons for RBC transfusion after randomization (N)
Hemoglobin level 4 6
Anemic symptoms 10 7
Both 7 8
Unknown 0 5
Health related Quality of Life scores (VAS mean  SD)**
T = −3 months 55.0  16.0 (N = 8) 69.4  14.5 (N = 9)
T = 0 57.5  13.1 (N = 8) 70.6  12.4 (N = 8)
T = 6 weeks 58.8  9.5 (N = 8) 61.3  16.6 (N = 8)
T = 3 months 62.9  11.1 (N = 7) 65.0  15.3 (N = 7)
T = 6 months 64.2  9.2 (N = 6) 70.8  12.8 (N = 6)
T = 9 months 68.8  6.3 (N = 4) 73.0  10.4 (N = 5)
T = 12 months 58.3  20.2 (N = 3) 73.8  11.1 (N = 4)
Physical Fatigue scores (Mean  SD)***
T = −3 months 13.8  3.3 (N = 8) 13.0  4.2 (N = 7)
T = 0 12.1  5.4 N = 8) 10.3  4.4 (N = 7)
T = 6 weeks 12.1  4.6 (N = 8) 12.6  6.3 (N = 8)
T = 3 months 11.7  5.7 (N = 6) 10.3  5.2 (N = 7)
T = 6 months 11.5  3.0 (N = 6) 10.7  4.3 (N = 6)
T = 9 months 12.3  2.5 (N = 4) 8.4  2.6 (N = 5)
T = 12 months 11.3  4.9 (N = 3) 9.0  2.9 (N = 4)
A = Hemoglobin transfusion trigger <4.5 mmoL/L or < 7.3 g/dL; B = Hemoglobin transfusion trigger <6.0 mmoL/L or < 9.7 g/dL; *according to
FAB criteria3; **Mean health related quality of life (HRQoL) scores  SD measured with the visual analogue scale of the EuroQoL5D question-
naire (range 0–100, the higher the score the better the HRQoL)2; ***Mean physical fatigue scores  SD measured with the Multidimensional
Fatigue Inventory questionnaire (range 4–20, the higher the score the more fatigue).2
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INTERCEPT pathogen-reduced platelets are
not associated with higher rates of
alloimmunization with (or without) clinical
refractoriness in published studies
Reduced count increments (CIs) after platelet concentrate
(PC) transfusion are most commonly caused by the patients’
underlying condition, including fever, sepsis, hemorrhage,
splenomegaly, and medications. Pathogen-reduced platelet
concentrates (PR-PCs) effectively prevent and/or treat
clinically-significant hemorrhage but may result in lower
CIs than equivalent doses of conventional platelets and
therefore incidently meet the definition of clinical refractori-
ness (commonly defined as two consecutive corrected count
increments [CCIs] of ≤5,000 when transfusing fresh, ABO
matched PC). Infanti et al. show that in routine use,
61.6–77.6% (mean 75.8%) of conventional PC and
58.2–75.2% (mean 64.6%) of amotosalen/UVA treated PR-PC
(INTERCEPT Blood System, Cerus Corp.) achieved
CCI’s ≥ 5,000 in various patient populations.1 These data
imply that by chance alone, ([1.0–0.758]2 = 0.059) 5.9% of
consecutive conventional and ([1.0-0.646]2 = 0.125) 12.5% of
consecutive INTERCEPT PC transfusions will meet the defi-
nition of clinical refractoriness. Alloimmunization to HLA
class I or platelet specific antigens (e.g., PLA1) is a relatively
infrequent cause but may be associated with life-threatening
resistance to PC therapy and an increased risk of hemor-
rhagic death. The question remains whether INTERCEPT
PCs, the only approved PR technology for platelets in the
US, are associated with increased alloimmunization as a
cause of refractoriness?
The answer is not fully known, however a general fail-
ure to adequately differentiate between available PR tech-
nologies, as well as two recent Cochrane Library meta-
analyses serve to obfuscate the issue.2 In 2013, Butler et al.3
published a meta-analysis of four randomized controlled
studies that included 496 INTERCEPT PC and 509 conven-
tional PC-treated patients, and showed no significant differ-
ence in the incidence of platelet refractoriness with
alloimmunization (Risk ratio 1.53, 95% confidence interval
[CI] 0.80, 2.95). Subsequently Estcourt et al. included the
IPTAS study, referencing two abstracts as a source of data.2
A strong association between INTERCEPT PC and refractori-
ness with alloimmunization was concluded, rendering the
overall risk in favor of conventional PC. Surprisingly, neither
the quoted abstracts, the initial IPTAS study report,4 nor a
subsequent analysis of alloimmunization in IPTAS by Norris
et al.,5 actually presented the number of patients shown to
have both clinical refractoriness and alloimmunization.
Importantly, Norris et al. state that there was a three-fold
reduction that did not reach statistical significance, in high
strength HLA class I alloimmunization in patients treated
with INTERCEPT PC versus conventional PC.5 Data suggest
that high strength HLA class I antibodies are associated with
platelet refractoriness, while mid- to low-strength antibodies
are not.6
With these uncertainties, we reviewed the primary data
relating to alloimmunization in the IPTAS study. Rebulla
et al.4 reported clinical refractoriness in 15/109 (13.8%)
INTERCEPT PC and 5/107 (4.7%) Control PC recipients,
incidences remarkably similar to that predicted by chance
alone in the recently published Basel experience (12.5% and
5.9%, respectively).1 Of the 20 clinical refractory patients
(Test or Control),4 HLA antibody data were missing for four
patients due to lack of sample availability, and two Control
and five INTERCEPT PC patients had detectable HLA class I
antibodies at baseline (low-medium strength, normalized
doi:10.1111/trf.15722
© 2020 AABB
Volume 60, April 2020 TRANSFUSION 881
LETTERS
